JP2024512793A - セフチブテン投与レジメン - Google Patents

セフチブテン投与レジメン Download PDF

Info

Publication number
JP2024512793A
JP2024512793A JP2023561040A JP2023561040A JP2024512793A JP 2024512793 A JP2024512793 A JP 2024512793A JP 2023561040 A JP2023561040 A JP 2023561040A JP 2023561040 A JP2023561040 A JP 2023561040A JP 2024512793 A JP2024512793 A JP 2024512793A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
ceftibuten
group
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512793A5 (enExample
Inventor
デイビッド シー． グリフィス，
オルガ ロモフスカヤ，
エリザベス イー． モーガン，
ジェフリー エス． ルーティット，
Original Assignee
キューペックス バイオファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キューペックス バイオファーマ， インコーポレイテッド filed Critical キューペックス バイオファーマ， インコーポレイテッド
Publication of JP2024512793A publication Critical patent/JP2024512793A/ja
Publication of JP2024512793A5 publication Critical patent/JP2024512793A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023561040A 2021-04-05 2022-03-31 セフチブテン投与レジメン Pending JP2024512793A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170936P 2021-04-05 2021-04-05
US63/170,936 2021-04-05
PCT/US2022/071479 WO2022217199A1 (en) 2021-04-05 2022-03-31 Ceftibuten dosing regimens

Publications (2)

Publication Number Publication Date
JP2024512793A true JP2024512793A (ja) 2024-03-19
JP2024512793A5 JP2024512793A5 (enExample) 2025-03-03

Family

ID=83545863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561040A Pending JP2024512793A (ja) 2021-04-05 2022-03-31 セフチブテン投与レジメン

Country Status (11)

Country Link
US (1) US20240197750A1 (enExample)
EP (1) EP4319760A4 (enExample)
JP (1) JP2024512793A (enExample)
KR (1) KR20230167077A (enExample)
CN (1) CN117157078A (enExample)
AU (1) AU2022254114A1 (enExample)
BR (1) BR112023020348A2 (enExample)
CA (1) CA3212788A1 (enExample)
MX (1) MX2023011483A (enExample)
TW (1) TW202304430A (enExample)
WO (1) WO2022217199A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016116892A1 (en) * 2015-01-24 2016-07-28 Wockhardt Limited Antibacterial compositions
JP2019527196A (ja) * 2016-06-30 2019-09-26 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
JP2019532928A (ja) * 2016-09-16 2019-11-14 エンタシス・セラピューティックス・リミテッド ベータラクタマーゼ阻害剤化合物
WO2020112542A1 (en) * 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
JP2020519684A (ja) * 2017-05-10 2020-07-02 アリクサ ファーマシューティカルズ、インコーポレイテッド ベータ−ラクタマーゼ阻害剤およびその使用
WO2021041616A1 (en) * 2019-08-29 2021-03-04 Arixa Pharmaceuticals, Inc. Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017295866A1 (en) * 2016-07-14 2019-01-17 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
US12636297B2 (en) * 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016116892A1 (en) * 2015-01-24 2016-07-28 Wockhardt Limited Antibacterial compositions
JP2019527196A (ja) * 2016-06-30 2019-09-26 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
JP2019532928A (ja) * 2016-09-16 2019-11-14 エンタシス・セラピューティックス・リミテッド ベータラクタマーゼ阻害剤化合物
JP2020519684A (ja) * 2017-05-10 2020-07-02 アリクサ ファーマシューティカルズ、インコーポレイテッド ベータ−ラクタマーゼ阻害剤およびその使用
WO2020112542A1 (en) * 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2021041616A1 (en) * 2019-08-29 2021-03-04 Arixa Pharmaceuticals, Inc. Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOMOVSKAYA, OLGA ET AL.: ""Spectrum of Beta-Lactamase Inhibition by the Cyclic Boronate QPX7728, an Ultrabroad-Spectrum Beta-", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 64, no. 6, JPN6026013221, 21 May 2020 (2020-05-21), ISSN: 0005831975 *
STEWART, ADAM G ET AL.: ""Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae u", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 75, no. 9, JPN6026013222, 22 May 2020 (2020-05-22), pages 2384 - 2393, ISSN: 0005831976 *

Also Published As

Publication number Publication date
MX2023011483A (es) 2023-10-03
US20240197750A1 (en) 2024-06-20
EP4319760A1 (en) 2024-02-14
TW202304430A (zh) 2023-02-01
WO2022217199A1 (en) 2022-10-13
CN117157078A (zh) 2023-12-01
KR20230167077A (ko) 2023-12-07
CA3212788A1 (en) 2022-10-13
AU2022254114A1 (en) 2023-09-21
EP4319760A4 (en) 2025-01-08
BR112023020348A2 (pt) 2023-11-21

Similar Documents

Publication Publication Date Title
US20240197750A1 (en) Ceftibuten dosing regimens
KR102603489B1 (ko) 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
US9522129B2 (en) Pharmaceutical Combination
TWI423802B (zh) 用於治療阿茲海默症之藥劑
US20010006972A1 (en) Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
WO2020259528A1 (zh) 治疗特发性肺纤维化的方法
KR102789783B1 (ko) 항혈소판제와 산 분비 억제제를 포함하는 약학 조성물
CN112166111A (zh) 治疗纤维化疾病的方法
RU2290929C2 (ru) Фармацевтическая композиция для лечения интерстициального цистита
EP0873753A1 (en) Use of NK-1 receptor antagonists for the manufacture of a medicament in the treatment of symptoms of irritable bowel syndrome
EP3600276B1 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
JP2024524372A (ja) セフチブテンの結晶形態
US20090118299A1 (en) Agent for prevention or treatment of glaucoma
CN119233823A (zh) 硼化合物治疗非结核分枝杆菌感染的方法和用途及用于治疗相同疾病的药物组合物
JP5339840B2 (ja) 抗ｘｄｒ−ｔｂ薬、抗ｍｄｒ−ｔｂ薬、及び併用抗結核薬
JPS59206309A (ja) 急発作障害の処置及びそれに有用な製薬組成物
US20240245666A1 (en) Dosing regimens
CN115715191B (zh) 排尿症状治疗剂
US20240075041A1 (en) Treatment of eosinophilic disorders with avapritinib
US20040087513A1 (en) New drug combinations based on sodium channel blockers and magnesium salts
TW202140006A (zh) 用於治療肝性腦病變之新穎藥物
WO2018016596A1 (ja) ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤
EP1572179B1 (en) Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor
CN120035442A (zh) 治疗尘肺病的方法
KR20250033290A (ko) 과민성 장 증후군을 위한 퀴놀론 화합물을 포함하는 제약 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260701